The patient was an 84-year-old man patient diagnosed as malignant pleurisy associated with lung cancer. After drainage of the right pleural effusion, pleurodesis with distilled water was performed. Despite the enlargement of the primary lesion of the lung cancer during the follow-up period, the amount of pleural effusion did not increase for more than one year. No adverse effects associated with pleurodesis were noted. Pleurodesis with distilled water should be considered as one of the choices for treatment in the management of malignant pleurisy especially in elderly.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.48.1762 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
Lung Cancer
December 2024
Department of Chemotherapy, Japan Red Cross Medical Center, Shibuya, Tokyo 150-8935, Japan.
Background: Although clinical trials of systemic chemotherapy for advanced non-small-cell lung cancer (NSCLC) have included both postoperative recurrence and de novo unresectable cases, postoperative recurrence is reported to have a better efficacy and prognosis. However, there are no efficacy data of first-line osimertinib for postoperative recurrence.
Methods: We conducted a post hoc analysis of a multicenter, prospective, observational study that evaluated the efficacy of first-line osimertinib in patients with epidermal growth factor receptor (EGFR)-positive NSCLC.
Lenvatinib treatment strategy for thyroid carcinoma with malignant pleurisy: a case report.
Gland Surg
October 2024
Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health, Biosciences, The University of Tokushima, Tokushima, Japan.
Background: Although lenvatinib is effective for unresectable thyroid carcinoma, it may cause adverse events owing to rapid tumor shrinkage or necrosis. Pneumothorax during lenvatinib therapy is rare. However, once it occurs, it can become a refractory and fatal complication.
View Article and Find Full Text PDFPhase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study).
Transl Lung Cancer Res
October 2024
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Background: The prognosis of patients with lung cancer and malignant pleural effusion (MPE) caused by carcinomatous pleurisy is poor. Chemical pleurodesis is commonly performed clinically, however, often has a high failure rate. Furthermore, prolonged sustained drainage and delayed introduction of systemic chemotherapy could increase the risk of worsening the Eastern Cooperative Oncology Group Performance Status (ECOG PS) in the treatment of patients with non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFHigh endothelial venules in the pleura: MECA-79 expression in mesothelioma, pleural metastasis and pleuritis.
Pathol Res Pract
November 2024
Pathology Department, University Hospital of Saint-Etienne, Saint-Etienne, France. Electronic address:
Article Synopsis
- High endothelial venules (HEVs) are specialized blood vessels that help lymphocytes move from blood into tissues, and this study is the first to investigate their presence in pleural tissue associated with tumors.
- The researchers analyzed 149 surgical pleural biopsies, using immunohistochemistry to identify HEVs, finding them in 68% of the samples, with a higher occurrence in neoplastic diseases compared to non-neoplastic ones.
- The findings suggest that HEVs play a role in the immune response within pleural diseases, highlighting their significance in both inflammatory and cancer-related conditions in the pleural cavity.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!